Breast Cancer Research and Treatment **40**: 295, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 40

Adenis A 161
Alm P 187
Alonso DF 209
Auerbach L 257
Ayanian JZ 65

Bal De Kier Joffé E 209
Beaver J 251
Bell JA 251
Betancor P 265
Birsak CA 243
Blamey RW 251
Bonneterre J 161
Breen N 105
Brown M 105

Chen L-C 271
Chirino R 265
Colangelo D 151
Colavito P 151
Collins C 271
Colucci G 151
Coviello M 151
Croce CM 171

Das R 141
Davel L 209
Deng G 271
Desch C 75
Diamandis EP 171
Díaz-Chico B 265

Earishi M 179
Eder H 257
Eder S 205
Ellis IO 251
Erlichman C 225

Farías EF 209
Fournier C 161

Giai M 171
Gilot N 231
Giotta F 151
Groot K 129
Guadagnoli E 65

Hadiy S 231
Halmos G 129
Hecquet B 161
Hiatt RA 37
Hillner BE 75
Hoff MS 119
Huber JC 205
Hughes C 25

Ingvar C 187

Janssen PJA 243
Jernström H 187
Jönsson P-E 187

Kainz C 257
Kallioniemi A 271
Katev N 283
Kerlikowske K 53
Kerner JF 1
Kessler L 105
Koebl H 257
Kreipe H 187
Kurisu W 271

Ladeda V 209
Leclerq G 231
Lerman C 25
Levesque M 171
Linas BP 87
Liu F-F 225
Lustbader E 25

Maiello E 151
McDonald MK 75
McLachlan S-A 225
Miller N 225
Minami M 179
Miyazaki I 179,283
Mizukami Y 179
Monne M 171
Moore D 271
Morales M 265
Mosquera A 265
Muquardt C 231

Nagy A 129
Noguchi M 179,283
Nonomura A 179
Nóvoa J 265

Olsson H 187
Ordovás J 265

Pasick RJ 37
Penberthy L 75
Petal D 231
Peterse JL 243
Piccart M 231
Pinder S 251
Pintilie M 225
Ponzone R 171
Puricelli L 209

Quaranta M 151

Rella C 151
Retchin SM 75
Roagna R 171
Robertson JFW 251
Rydén S 187

Santana N 265
Saunders F 197
Schally AV 129
Schittulli F 151
Schneeberger C 205,257
Schulman K 87
SenGupta S 197
Severson RK 119
Simon MS 119
Sismondi P 171
Sliutz G 205,257
Smith DW 119
Smith HS 271
Smith TJ 75
Soria A 265
Stano M 119
Sterns EE 197
Szepeshazi K 129
Szoke B 129

Taniya T 179
Tantscher E 205
Tempfer C 257
Trivedi S 231
Trock BJ 11
Tschuggel W 205

Valerón PF 265
van der Kwast ThH 243
van Vroonhoven CCJ 243
Vanlemmens L 161
Vonderhaar 141

Waldman FM 271
Willsher PC 251

Yabroff KR 87
Yu H 171
Yu M 271

Zee B 197
Zeillinger R 205,257

Breast Cancer Research and Treatment **40**: 297-300, 1996.
© 1996 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 40

adjuvant therapy
variation in staging and treatment in the elderly 75-86
age
and access to standard breast care 105-115
treatment variations by patient and provider characteristics 65-74
variation in staging and treatment in the elderly 75-86
amplification
new "differentially competitive" PCR method — erbB-2 and chromosome 20q 271-281
androgen receptor
in carcinoid tumors of the breast 243-249
angiogenesis
vascularity by Doppler ultrasound vs. factor VIII IHC, and outcome 197-203
animal models
cytotoxic LH-RH analog T-98 — inhibition of hormone-dependent mouse MXT model 129-139
apolipoproteins
improved profile with tamoxifen treatment 265-270
argyrophilic cells
and steroid receptors in carcinoid tumors of the breast 243-249
avoidance behavior
ethnic/cultural differences in risk perception 25-35
axillary metastases
review of diagnostic approaches 283-293
axillary sampling
intraoperative assessment of need for level III dissection 179-185

benign breast disease
higher levels of prostate specific antigen (PSA) than in cancer 171-178

cancer control
determinants of access 105-115
prevention and control among the under-served (special issue) 1-115
carcinoid tumors of the breast
steroid receptor content 243-249
cardiovascular disease
improved serum lipid and apolipoprotein profile with tamoxifen 265-270
chemotherapy
CMF activation of hypercoagulation 151-159
cholesterol
reduction by tamoxifen treatment 265-270
chromogranin A
in carcinoid tumors of the breast 243-249
chromosome 20q
delineation of amplicon by differentially competitive PCR method 271-281
coagulation factors
activation during CMF chemotherapy 151-159
conservative treatment
allowed by mitoxantrone/vinorelbine neo-adjuvant treatment 161-169
cost analysis
of clinical follow-up for early stage breast cancer 119-128
cultural diversity
and appropriateness of quality of life instruments 87-104

EGF receptors
reduction by LH-RH cytotoxic analog in hormone-dependent mouse model 129-139
epidemiology
prevention and control among the under-served (special issue) 1-115
erbB-2 oncogene
amplification by new "differentially competitive" PCR method 271-281
erbB-2 oncogene protein
in serum, and poor prognosis 251-255
estrogen receptor
correlated with presence of nitric oxide synthase 205-207
in carcinoid tumors of the breast 243-249
tamoxifen aziridine labelling of aberrant forms 231-241

ethnicity
differences in risk perception 25-35
prevention and control among the under-served (special issue) 1-115
see also race

family history
and higher proliferation rate of normal breast tissue 187-196
fibronectin
effect of urokinase inhibitors on invasion-associated proteolysis 209-223
functional status
by quality-of-life instruments in diverse cultures 87-104

gene amplification
new "differentially competitive" PCR method — erbB-2 and chromosome 20q 271-281

health services access
individual, socioeconomic, and health system determinants 105-115
health state preferences
by quality-of-life instruments in diverse cultures 87-104
hemostatic factors
CMF activation of hypercoagulation state 151-159
HER-2/*neu* oncogene
see erbB-2

induction chemotherapy
mitoxantrone/vinorelbine allows conservative treatment 161-169
intervention
community-based, for screening in different ethnic and socioeconomic groups 37-51
invasion
effect of synthetic urokinase inhibitors 209-223

Ki-S1 antibody
as a marker of proliferation rate 187-196

LH-RH agonists
cytotoxic analog T-98 — inhibition of hormone-dependent mouse MXT model 129-139
lipoproteins
improved profile with tamoxifen treatment 265-270
lymph node metastases
intraoperative axillary sampling to assess need for level III dissection 179-185
review of diagnosis of axillary node metastasis 283-293
lymphoscintigraphy
in diagnosis of axillary metastases — review 283-293

male breast cancer
review of 66 cases 225-230
mammography
in diagnosis of axillary metastases — review 283-293
timeliness of follow-up after abnormal 53-64
MAP kinase
prolactin activation in responsive mammary cells 141 149
medically under-served populations
prevention and control (special issue) 1-115
MEK (MAP kinase kinase)
prolactin activation in responsive mammary cells 141-149
menstrual cycle
higher proliferation of normal breast tissue in luteal phase 187-196
metastasis
effect of synthetic urokinase inhibitors 209-223
minorities
prevention and control among the under-served (special issue) 1-115
mitoxantrone
with vinorelbine as induction chemotherapy allows conservative treatment 161-169
molecular markers
African-American vs. white women 11-24
mouse mammary cancer
inhibition of MXT model by cytotoxic LH-RH analog T-98 129-139

neo-adjuvant chemotherapy
mitoxantrone/vinorelbine induction therapy allows conservative treatment 161-169
nitric oxide synthase
correlated with estrogen receptor 205-207

nuclear magnetic resonance
in diagnosis of axillary metastases — review 283-293

pathology
in breast tumors of African-American vs. white women 11-24
plasminogen activator
see urokinase plasminogen activator
polymerase chain reaction (PCR)
"differentially competitive" PCR for erbB-2 and chromosome 20q amplification 271-281
RT-PCR in detection of nitric oxide synthase and ER in breast cancer lines 205-207
RT-PCR in uPA receptor quantitation in cell lines 257-263
practice patterns
follow-up surveillance variations and costs 119-128
variation in staging and treatment in the elderly 75-86
variations by patient and provider characteristics 65-74
prevention
and control among the under-served (special issue) 1-115
progesterone receptor
in carcinoid tumors of the breast 243-249
prognostic factors
in male breast cancer 225-230
serum c-erbB-2 protein 251-255
vascularity (Doppler ultrasound) vs. proliferation, grade, ER, and outcome 197-203
prolactin
activation of *raf*-1, MEK, and MAP kinase in responsive mammary cells 141-149
proliferation rate
Ki-S1 antigen as a marker 187-196
of normal breast tissue, vs. family history, menstrual cycle phase, and hormone use 187-196
prostate specific antigen (PSA)
highest in benign breast disease and early-stage cancer 171-178
protease inhibitors
effect of synthetic urokinase inhibitors on invasion and metastasis 209-223

quality of life
appropriateness of instruments in diverse cultures 87-104

race
and access to standard breast care 105-115
prevention and control among the under-served (special issue) 1-115
risk factors and molecular markers in African-American vs. white women 11-24
treatment variations by patient and provider characteristics 65-74
raf-1
rapid activation by prolactin in responsive mammary cells 141 149
risk factors
African-American vs. white women 11-24
risk perception
ethnic differences and screening behavior 25-35

screening
ethnic/cultural differences in risk perception 25-35
factors relating to access 105-115
prevention and control among the under-served (special issue) 1-115
race vs. socioeconomic status as inhibiting factors 37-51
timeliness of follow-up after abnormal mammogram 53-64
signal transduction
prolactin activation of kinases in responsive mammary cells 141-149
socioeconomic status
and access to standard breast care 105-115
prevention and control among the under-served (special issue) 1-115
principal correlate of non-screening 37-51
treatment variations by patient and provider characteristics 65-74
special issue
prevention and control among the under-served 1-115
surgery
intraoperative axillary assessment — review 283-293
intraoperative axillary sampling to assess need for level III dissection 179-185

surgery *continued)*
variation in staging and treatment in the elderly 75-86
surveillance
study of clinical follow-up costs 119-128

T47D human breast cancer cells
prolactin activation of kinases 141-149
tamoxifen
improvement in serum lipid and apolipoprotein profile 265-270
tamoxifen aziridine
in labelling of aberrant ER forms 231-241
thermography
abnormalities associated with higher vascularity (Doppler ultrasound) 197-203
thrombosis
CMF activation of hypercoagulation 151-159
tracking
system to insure timely follow-up of abnormal mammogram 53-64
treatment
variations by patient and provider characteristics 65-74
variations in the elderly 75-86
tumor biology
African-American vs. white women 11-24

ultrasonography
in diagnosis of axillary metastases — review 283-293
urokinase inhibitors
effect on invasion and metastasis 209-223
urokinase plasminogen activator (uPA) receptor
and invasiveness in cell lines 257-263

vascularity
by Doppler ultrasound vs. factor VIII IHC, and outcome 197-203
vinorelbine
with mitoxantrone as induction chemotherapy allows conservative treatment 161-169